Seminars in nephrology最新文献_第4页

Updates on IgA Nephropathy. IgA肾病的最新进展。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-12 DOI: 10.1016/j.semnephrol.2025.151574

Dana V Rizk

引用次数: 0

Post-transplant IgA Nephropathy. 移植后IgA肾病。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-13 DOI: 10.1016/j.semnephrol.2025.151570

Song C Ong, Bruce A Julian

引用次数: 0

The Journey to Advocacy: Celebrating the IgA Nephropathy Foundation's 20th Anniversary. 倡导之旅：庆祝IgA肾病基金会成立20周年。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-17 DOI: 10.1016/j.semnephrol.2025.151575

Brian Parlato

{"title":"The Journey to Advocacy: Celebrating the IgA Nephropathy Foundation's 20th Anniversary.","authors":"Brian Parlato","doi":"10.1016/j.semnephrol.2025.151575","DOIUrl":"10.1016/j.semnephrol.2025.151575","url":null,"abstract":"<p><p>The IgA Nephropathy Foundation was established in 2004 by Bonnie and Ed Schneider, the concerned parents of a young boy diagnosed with IgA nephropathy (IgAN). At the time the Foundation was established, patients had trouble finding the most basic information about IgAN, and few nephrologists had experience with this rare disease. Celebrating its 20th anniversary this year, the Foundation has been instrumental in bringing the IgAN community together through research grants, advocating for patients and caregivers, offering patient support services, and becoming the go-to source for information and education. A big focus for the Foundation is communicating the \"voice of the patient\" to the medical community to help identify needs and provide insight into the lives of IgAN patients and caregivers. The Foundation is very active in getting the word out, attending the last two International Symposia on IgA Nephropathy, in Prague, Czech Republic, and Tokyo, Japan. The Foundation also sponsored the IgA Nephropathy Seminar Day at the 6th CKD Summit in Boston in spring 2024. This article chronicles some of the Foundation's key milestones, highlights patient-facing and point-of-care resources, and provides key insights into the patient experience as well as tips for how clinicians can best meet patients where they are, bridge gaps, and improve care. The unmet needs of the IgAN community continue to drive the IgA Nephropathy Foundation's purpose and steadfast commitment to finding a cure for this rare disease.</p>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":" ","pages":"151575"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Genetics of IgA Nephropathy: Implications for Future Therapies. IgA肾病的遗传学：对未来治疗的影响。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-13 DOI: 10.1016/j.semnephrol.2025.151567

Xu-Jie Zhou, Hong Zhang

引用次数: 0

IgAN Across the Age Spectrum: The Pediatric Perspective. 跨年龄谱IgAN：儿科视角。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-12 DOI: 10.1016/j.semnephrol.2025.151569

Licia Peruzzi, Rosanna Coppo

引用次数: 0

Current Biomarkers of IgA Nephropathy. 当前IgA肾病的生物标志物。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-13 DOI: 10.1016/j.semnephrol.2025.151572

Fahmeedah Kamal, Jackson Kim, Richard Lafayette

引用次数: 0

Emerging Biochemical and Immunologic Mechanisms in the Pathogenesis of IgA Nephropathy. 新出现的IgA肾病发病机制的生化和免疫机制。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-13 DOI: 10.1016/j.semnephrol.2025.151565

Jan Novak, Colin Reily, Nicholas J Steers, Tillie Schumann, Dana V Rizk, Bruce A Julian, Krzysztof Kiryluk, Ali G Gharavi, Todd J Green

{"title":"Emerging Biochemical and Immunologic Mechanisms in the Pathogenesis of IgA Nephropathy.","authors":"Jan Novak, Colin Reily, Nicholas J Steers, Tillie Schumann, Dana V Rizk, Bruce A Julian, Krzysztof Kiryluk, Ali G Gharavi, Todd J Green","doi":"10.1016/j.semnephrol.2025.151565","DOIUrl":"10.1016/j.semnephrol.2025.151565","url":null,"abstract":"<p><p>IgA nephropathy is a mesangioproliferative glomerular disease with significant morbidity and mortality. Most patients with IgA nephropathy develop kidney failure in their lifetime, reducing their life expectancy by a decade. Since its first description in 1968, it has been established that kidneys of IgA nephropathy patients are injured as \"innocent bystanders\" by nephritogenic IgA1-containing immune complexes. Results from clinical, biochemical, immunologic, and genetic studies suggest a multistep pathogenetic mechanism. In genetically predisposed individuals, this process results in formation of circulating immune complexes due to the binding of IgG/IgA autoantibodies to the polymeric IgA1 molecules with incomplete O-glycosylation. This event is followed by the addition of other proteins, such as complement C3, resulting in the formation of nephritogenic immune complexes. These complexes are not effectively removed from the circulation, and some of them pass through the fenestration of glomerular endothelial cells to enter the mesangial space and activate mesangial cells. It is thought that the process is initiated by soluble immune complexes and that their accumulation results in the formation of immunodeposits that further amplify glomerular injury. Here we summarize current understanding of the pathogenesis of IgA nephropathy and discuss experimental model systems that can inform development of new therapeutic strategies and targets.</p>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":" ","pages":"151565"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Rapidly Changing Treatment Landscape of IgA Nephropathy. 快速变化的IgA肾病治疗前景。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-09-01 Epub Date: 2025-03-07 DOI: 10.1016/j.semnephrol.2025.151573

Chee Kay Cheung, Jonathan Barratt

引用次数: 0

Measuring Social Functioning in Chronic Kidney Disease 衡量慢性肾脏病患者的社会功能。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-05-01 DOI: 10.1016/j.semnephrol.2024.151547

Amanda Sluiter MRMed , Anita van Zwieten PhD , Jenny I. Shen MD , Karine Manera PhD

{"title":"Measuring Social Functioning in Chronic Kidney Disease","authors":"Amanda Sluiter MRMed , Anita van Zwieten PhD , Jenny I. Shen MD , Karine Manera PhD","doi":"10.1016/j.semnephrol.2024.151547","DOIUrl":"10.1016/j.semnephrol.2024.151547","url":null,"abstract":"<div><div>Social functioning is a key aspect of daily life and is important to patients living with chronic kidney disease (CKD) and their caregivers. Many patients with CKD experience debilitating symptoms and treatment burden that can diminish their social functioning and thereby overall social health, which is the aspect of a person's well-being relating to their interactions and connections with others. In patients with CKD, symptoms (e.g., fatigue and pain), burden of ongoing treatments (including kidney replacement therapies), and medication side effects can impair social functioning. Having to manage responsibilities of self-management, which can include time-consuming and invasive treatments such as dialysis, can severely limit social functioning in patients with CKD. This can lead to poor social connections at many levels, including with family, friends, peers, and colleagues, and can hinder the development of new relationships. Patients with CKD with poorer social functioning have been reported to have worse quality of life and impaired mental health. Many patients with CKD rely on an informal caregiver—usually a family member or friend—to assist with management of their disease. This can place strain on the caregiver, further limiting opportunities for social connections for both the patient and caregiver. Although social functioning is critical for the overall well-being of patients with CKD, it remains underaddressed clinically, and patient-reported outcome measures (PROMs) to assess social functioning are limited. The objective of this article is to define social functioning, discuss the impacts of social functioning in patients with CKD and their caregivers, outline PROMs that have included assessment of social functioning, and discuss considerations in developing an appropriate PROM to measure social functioning in patients with CKD. This may help to inform the evaluation of interventions and care regarding social functioning within the CKD population.</div></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"44 3","pages":"Article 151547"},"PeriodicalIF":2.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142111919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Core Patient-Reported Outcomes for Trials in Nephrology 肾内科试验的核心患者报告结果。

IF 2.8 3区医学

Seminars in nephrology Pub Date : 2024-05-01 DOI: 10.1016/j.semnephrol.2024.151549

Anastasia Hughes BPH , Nicole Scholes-Robertson PhD , Angela Ju PhD , Allison Jauré PhD

{"title":"Core Patient-Reported Outcomes for Trials in Nephrology","authors":"Anastasia Hughes BPH , Nicole Scholes-Robertson PhD , Angela Ju PhD , Allison Jauré PhD","doi":"10.1016/j.semnephrol.2024.151549","DOIUrl":"10.1016/j.semnephrol.2024.151549","url":null,"abstract":"<div><div>The outcomes reported in trials across all stages of chronic kidney disease (CKD) are highly variable and often do not include outcomes that are directly relevant to patients and caregivers. Frequently, the outcomes reported in trials are often unvalidated surrogate biochemical end points. The omission of outcomes that are meaningful and important to patients can diminish the value of trials in supporting treatment decisions. In response, there have been increasing efforts across many health and medical disciplines to develop core outcome sets, defined as the minimum set of outcomes to be reported in all trials in a specific health area to improve the relevance and consistency of reporting trial outcomes. The international Standardized Outcomes in Nephrology (SONG) initiative was established in 2014 and has since developed seven core outcome sets for different diagnosis and treatment stages of CKD. The core outcomes were based on consensus among patients, caregivers, and health professionals. Each core outcome set includes at least one patient-reported outcome, including fatigue (hemodialysis), life participation (kidney transplantation, peritoneal dialysis, early CKD not yet requiring kidney replacement therapy, children and adolescents, and glomerular disease), and pain (polycystic kidney disease). This article outlines how patient-reported outcomes are currently reported in trials, discusses core patient-reported outcomes that have been established for trials in kidney disease, and outlines strategies for implementing core patient-reported outcomes in trials.</div></div>","PeriodicalId":21756,"journal":{"name":"Seminars in nephrology","volume":"44 3","pages":"Article 151549"},"PeriodicalIF":2.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0